View full meeting coverage »

Eyetube Meeting Coverage:

2017 American Academy of Ophthalmology

 

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

Head-to-Head Trials

  Channels: Retina | Posted 11/17/2017

Pravin Dugel, MD, examines data from the HAWK and HARRIER studies, evaluating the efficacy of brolucizumab (RTH258, Novartis) compared with aflibercept (Eylea, Regeneron) in the treatment of patients with neovascular age-related macular degeneration (AMD) in a matched, direct, head-to-head comparison over a period of 48 weeks. Dr. Dugel discusses the performance of the drugs during disease activity assessments at week 16 and scheduled at prespecified times thereafter, and he considers the role of brolucizumab in disease control and in more sustainable treatment strategies moving forward.

HAWK and HARRIER


5 / 26 Series: 2017 American Academy of Ophthalmology


More Videos in this Series


View full meeting coverage (26 videos)
This program is not affiliated with the official program of AAO 2017.